Kiora Pharmaceuticals: Funding, Investors & Team (Sep 2026)
Kiora is a clinical-stage specialty drug organization creating and commercializing items for treating ophthalmic infections. KIO-301 is a sub-atomic photoswitch that can possibly reestablish light discernment in patients with acquired as well as age-related retinal degeneration. KIO-101 is a future, non-steroidal, immuno-modulatory and little particle inhibitor of Dihydroorotate Dehydrogenase ("DHODH") with top tier picomolar power and an approved insusceptible balancing system (T cell expansion restraint) intended to beat the off-target secondary effects and wellbeing issues related with DHODH inhibitors. What's more, Kiora is creating KIO-201, a changed type of the regular polymer hyaluronic corrosive, intended to speed up corneal injury recuperating.
Kiora Pharmaceuticals has raised $14.1M across 3 funding rounds on record, the most recent an undisclosed round of $5.0M announced in Apr 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Kiora Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Apr 2026.
Kiora Pharmaceuticals Funding Rounds
Kiora Pharmaceuticals raised $6.0M in a Post-IPO Equity announced in Jul 2022.
4 months later, an undisclosed round of $3.1M was announced in Nov 2022.
3.4 years later, an undisclosed round of $5.0M was announced in Apr 2026.
Kiora Pharmaceuticals Founders and Leadership Team
Contact details for the Kiora Pharmaceuticals team: 1 of 3 have an email address on file.
Start 14-day free trial →Kiora Pharmaceuticals Funding Compared to Other Biotechnology Startups
Kiora Pharmaceuticals' latest round of $5.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Kiora Pharmaceuticals in Biotechnology and Salt Lake City
Companies Similar to Kiora Pharmaceuticals
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Kiora Pharmaceuticals Funding FAQs
What does Kiora Pharmaceuticals do?
Kiora is a clinical-stage specialty drug organization creating and commercializing items for treating ophthalmic infections. KIO-301 is a sub-atomic photoswitch that can possibly reestablish light discernment in patients with acquired as well as age-related retinal degeneration. KIO-101 is a future, non-steroidal, immuno-modulatory and little particle inhibitor of Dihydroorotate Dehydrogenase ("DHODH") with top tier picomolar power and an approved insusceptible balancing system (T cell expansion restraint) intended to beat the off-target secondary effects and wellbeing issues related with DHODH inhibitors. What's more, Kiora is creating KIO-201, a changed type of the regular polymer hyaluronic corrosive, intended to speed up corneal injury recuperating.
How much funding has Kiora Pharmaceuticals raised?
Kiora Pharmaceuticals has raised $14.1M across 3 rounds on record. The most recent is an undisclosed round of $5.0M announced in Apr 2026.
When did Kiora Pharmaceuticals last raise funding?
Kiora Pharmaceuticals' most recent funding round on record is an undisclosed round of $5.0M, announced in Apr 2026.
Who founded Kiora Pharmaceuticals?
FundedIQ lists Brian M (Founder) at Kiora Pharmaceuticals.
Who is the CEO of Kiora Pharmaceuticals?
Brian M Strem is listed as CEO at Kiora Pharmaceuticals.
Where is Kiora Pharmaceuticals headquartered?
Kiora Pharmaceuticals is based in Salt Lake City, Utah, United States.
How many employees does Kiora Pharmaceuticals have?
Kiora Pharmaceuticals is in the 11-50 employee band.
How does Kiora Pharmaceuticals' funding compare to other Biotechnology startups?
Kiora Pharmaceuticals' latest round of $5.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Kiora Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Kiora Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.